New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
April 13 2009 - 9:45AM
PR Newswire (US)
HUBBARD, Ohio, April 13 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(OTC: NNLX) a biotechnology company, is pleased to provide the
following information: An independent study has found that
NanoLogix's BNP(TM) Ultra-Fast Identification Technology allows the
viewing of anthrax cultures four times faster than conventional
methods. The study, by one of the foremost bio-defense and
biomedical research centers in the U.S., appears in the current
online issue of Letters in Applied Microbiology. The authors found
that NanoLogix's BNP(TM) technology displayed colonies of anthrax
in six hours, as contrasted with the fastest traditional methods,
which typically take 24 hours. The study also found that the
NanoLogix BNP(TM) technology allowed viewing of cultures of bubonic
plague, known historically as the "Black Death", twice as fast as
traditional Petri plate methods. The study, by an independent lab
under strict protocols, confirms the value of NanoLogix's
breakthrough technology when time is a crucial factor. The BNP(TM)
method has proven to be much faster than any other method in the
broad field of Petri dish testing. The authors of the study
concluded that the NanoLogix technology could lead to a more rapid
assessment of surface sampling and decontamination measures, and
could aid in the evaluation of medical countermeasures and
treatments. The study appears in the current online issue of
Letters in Applied Microbiology. Links to study:
http://www3.interscience.wiley.com/journal/122295541/abstracthttp://www.nanologix.com/downloads/NNLX%20-%20resource%203.pdf
NanoLogix's BNP(TM) Ultra Fast Identification Technology has
applications for fields outside the bio-defense arena as well,
including epidemiology, hospital diagnosis, veterinary medicine and
food safety. NanoLogix CEO Bret Barnhizer stated "We are elated
with the results of the study and look forward to increased public
awareness of the broad capabilities of the BNP(TM) Ultra-Fast kits.
We believe that the BNP(TM) sandwiched-membrane is the next
evolutionary step in Petri technology and will be the kit of choice
whenever faster test results are essential." The bacteria
responsible for Anthrax and Bubonic plague are category A select
agents, due to their capacity to cause illness and death. These
micro-organisms are a preferred bio-weapon of terrorists. As these
agents are highly dangerous all testing was done in a BioSafety
Level 3 laboratory (BSL-3). This is protocol required with category
A select agents, which can cause serious or potentially lethal
disease after inhalation. The BNP(TM) technology provided similar
colony counts for anthrax in 6 hours as obtained with the
traditional Petri method in 24 hours. For Bubonic plague, the
BNP(TM) colony count in 24 hours was also similar to what the
traditional methodology achieved in 48 hours. In 2001, letters
containing anthrax spores were mailed to several news media offices
and to the offices of two U.S. Senators, killing five people and
infecting 17 others, throwing the nation into a near panic. During
the first crucial hours of infection or threat, rapid confirmation
of the presence of biological agents can mean the difference
between life and death, between a widespread public panic and a
smooth containment strategy. In the event of future attacks such as
occurred in 2001, the hope is that the BNP's(TM) ability to assist
in determining the threat posed by biologic agents will contribute
to a more rapid diagnosis and response. About NanoLogix NanoLogix
is a biotechnology company focused primarily on medical
diagnostics. Its products offer accelerated detection and
identification of microorganisms present in infectious and
non-infectious human diseases, such as tuberculosis, NTM,
pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague.
In addition to medical and homeland security applications,
NanoLogix technology is applicable in pharmaceutical, industrial,
veterinary and environmental testing. Patents granted to NanoLogix
can be used in the areas of applied microbiology, soil microbiology
and bioremediation, microbial physiology, molecular biology,
pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell
research, and bioreactor-based hydrogen generation. More
information on NanoLogix is available at: http://www.nanologix.com/
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results. Contact: Investor Relations Carol Surrena
Telephone: 330-534-0800 E-mail: DATASOURCE: NanoLogix, Inc.
CONTACT: Investors, Carol Surrena of NanoLogix, Inc.,
+1-330-534-0800, Web Site: http://www.nanologix.com/
Copyright